Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Maximilian J Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour

Research output: Journal article (peer-reviewed) › Journal article

28 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science